BACKGROUND: Germline and tumor pharmacogenomics impact drug responses, but germline markers less commonly guide oncology prescribing. The authors hypothesized that a critical number of clinically actionable germline pharmacogenomic associations exist, representing clinical implementation opportunities. METHODS: In total, 125 oncology drugs were analyzed for positive germline pharmacogenomic associations in journals with impact factors 5. Studies were assessed for design and genotyping quality, clinically relevant outcomes, statistical rigor, and evidence of drug-gene effects. Associations from studies of high methodologic quality were deemed potentially clinically actionable, and translational summaries were written as point-of-care clinical decision support (CDS) tools and formally evaluated using the Appraisal of Guidelines for Research and Evaluation (AGREE) II instrument. RESULTS: The authors identified germline pharmacogenomic results for 56 of 125 oncology drugs (45%) across 173 publications. Actionable associations were detected for 12 drugs, including 6 that had germline pharmacogenomic information within US Food and Drug Administra- . By using AGREE II, the developed CDS summaries had high mean 6 standard deviation scores (maximum score, 100) for scope and purpose (92.7 6 5.1) and rigour of development (87.6 6 7.4) and moderate yet robust scores for clarity of presentation (58.6 6 25.1) and applicability (55.9 6 24.6). The overall mean guideline quality score was 5.2 6 1.0 (maximum score, 7). Germline pharmacogenomic CDS summaries for these 12 drugs were recommended for implementation. CONCLUSIONS: Several oncology drugs have actionable germline pharmacogenomic information, justifying their delivery through institutional pharmacogenomic implementations to determine clinical utility. Cancer 2018;124:3052-65.
INTRODUCTION
The discipline of pharmacogenomics aims to identify genetic variants that contribute to individual drug response to reduce adverse drug reactions and increase drug efficacy. Pharmacogenomic information plays a unique role in cancer therapy, because both the tumor (somatic) genome and the patient's germline genome can impact drug response. 1 Furthermore, because the consequences of drug toxicity can sometimes be particularly life-threatening in oncology, using pharmacogenomics to prevent such events is desirable. 2 Indeed, there is a rich history in oncology of germline pharmacogenomic variants playing a role in serious and life-threatening toxicities. Traditionally, germline variants of interest include those of drug-metabolizing enzymes, transporters, and other proteins involved in a drug's mechanism of action, 3 because such proteins are critical in determining the efficacy and toxicity of many chemotherapeutic agents. 4 Such germline pharmacogenomic information has been incorporated into US Food and Drug Administration (FDA) labels for capecitabine, 5 fluorouracil, 6 irinotecan, 7 6 mercaptopurine, 8 and thioguanine
9
; and Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines have been written for capecitabine/fluorouracil, 10 mercaptopurine/thioguanine, 11 and tamoxifen. 12 Although these well recognized examples already have established clinical implementation guidelines, other potential germline pharmacogenomic associations with strong supporting evidence have yet to be translated into clinical practice.
Increasingly, tumor pharmacogenomic information is incorporated into oncologic clinical decision making 13 ; and, in some cases, the use of oncology drugs is restricted to patients who carry explicit tumor mutations. 14, 15 Germline pharmacogenomic variants, in the more traditional sense (those involved in drug metabolism or mechanisms of action), less commonly guide oncology prescribing. Despite fervent, ongoing discovery research in the field, the current number of high-level, actionable germline pharmacogenomic markers in oncology is less clear than that for tumor genomics 16 and has been either outpaced or overshadowed by the routine clinical use of somatic markers. Regardless, incorporating actionable information about both tumor and germline genomics into cancer treatment plans has the potential to improve patient outcomes, yet clear recommendations or standardized guidelines are rarely available.
The objective of this report was to critically appraise the current germline pharmacogenomic discoveries in oncology using a prospective methodology to discover whether additional germline pharmacogenomic markers have sufficient evidence for clinical implementation. We sought to identify replicated, high-level evidence associations for which translation into clinical decision support (CDS) guidelines are warranted. Simultaneously, we aimed to identify associations for which intriguing germline pharmacogenomic data exist, yet evidence in support of implementation may be limited because of methodological limitations of current studies. We hypothesized that the findings will enable clinical consideration of germline variants and facilitate future examinations of clinical utility in practice.
MATERIALS AND METHODS

Data Collection
In total, 125 commonly prescribed cancer drugs were included 17 (Table 1 ). An automated search algorithm of "(drug name) polymorphism" in PubMed was used to identify pharmacogenomic publications for each drug. Articles examining the association between a germline genetic variant and a pharmacogenomic outcome were included. Specific exclusion criteria have been previously published 18 and are described in the Supporting Methods. Drug-genetic associations reported as being nominally statistically significant by the authors were recorded at first pass as "positive" in the database, whereas nonsignificant associations were labeled "negative."
All positive associations in a journal with a 5-year impact factor (IF) 5 were taken forward for critical analysis (as described below). To ensure that no important publications were missed by the automated PubMed algorithm, in February 2017, each drug was also manually searched in PubMed using our updated search string 18 (see Supporting Methods). The same process of manual inclusion/exclusion was performed for any additionally identified studies from journals with an IF 8.5, because the purpose of this second search was to identify any additional major findings (emphasizing specificity, whereas the first search emphasized sensitivity).
Data Analysis
Each positive drug-genetic association from the included articles was assessed using our previously described methodology 19 to determine whether the association was potentially clinically actionable (see also Supporting Methods). Studies using multidrug regimens were generally excluded from critical analysis, because direct attribution of a genetic association with a single drug could not be made. Exceptions were made for publications with specific drug-genetic pairs for which the variant or gene was implicated in a particular drug's activity or if a toxicity outcome studied was known to be associated with 1 particular drug. Similarly, studies reporting only associations with multivariant genetic haplotypes were excluded from our analysis, because we were interested in identifying single polymorphisms that could be clinically assessed. However, gene-level associations used for cytochrome P450 family 2 subfamily D member 6 (CYP2D6) or other similar genes with known enzymatic phenotypes (eg, "poor metabolizer"/"rapid metabolizer") were included.
The presence of large cohort sizes, control populations, high-quality phenotype measurements, treatment homogeneity among study participants, and appropriate statistical measures all increased support for clinical actionability. Drug-genetic pairs that were not statistically significant after multiple testing corrections were not deemed clinically actionable unless another well performed study supported the same genotype-phenotype association. Generally, drug-genetic pairs also were deemed not actionable if they were associated only with prognostic outcomes. Publications that studied response but included stable disease in the definition of clinical response were deemed not actionable. Associations from genome-wide association studies that did not meet genome-wide significance were not deemed actionable unless convincing replication or functional data existed.
Two independent reviewers considered the resulting drug-genetic pairs from the analysis described above. Dedicated, manual "(drug name) (variant rs number)" PubMed searches were separately conducted for each as part of this final step to ensure that no studies were missed.
Complementary to this comprehensive analysis, consideration of FDA label information, CPIC guidelines, and other published guidance (eg, PharmGKB, Dutch Pharmacogenomics Working Group) was given. Capecitabine, 5 fluorouracil, 6 irinotecan, 7 mercaptopurine, 8 and thioguanine 9 have germline pharmacogenomic information containing a recommended clinical action already incorporated into FDA labels. Capecitabine, fluorouracil, mercaptopurine, tamoxifen, and thioguanine have published CPIC guidelines. [10] [11] [12] Clinically actionable information for these 6 drugs, along with potentially actionable information for any other drugs that emerged from our comprehensive analysis, was taken forward for development into draft CDS summaries.
Finally, we considered germline genetic findings that represent gene-disease associations but which may also directly guide the prescribing of certain oncology drugs. The FDA Table of Pharmacogenomic Biomarkers in Drug Labeling 14 was analyzed for oncology drugs with germline gene-disease information included in the package labeling. We reviewed each drug label for actionable prescribing recommendations based on germline disease variants.
CDS Summary Development
CDS summaries that translated genetic information into point-of-care guidance were independently written by a member or members of the CDS development team using methods previously described 18 (see also Supporting Methods). The resulting draft CDS summaries were independently reviewed by 2 members of the evidence evaluation team (R.W. and P.H.O.) and were then subjected to formal Appraisal of Guidelines for Research and Evaluation (AGREE) II scoring.
AGREE II Scoring
We used a modified AGREE II 20 scoring instrument to determine whether each draft CDS summary warranted clinical implementation (see Supporting Methods for full details). Our modified AGREE II instrument included the specific items from the domains of scope and purpose, rigour of development, clarity of presentation, and applicability. Four independent appraisers (R.N., B.N.P., W.M.S., and M.J.R.) rated each draft summary on all 4 domains, gave each an overall score, and voted (independently) whether the summary deserved deployment as a clinical guideline. The AGREE appraisal of whether or not to recommend the summary was used as the final determination for inclusion into our institutional pharmacogenomic program. 21 Unless a summary received unanimous agreement in favor of clinical deployment, it was not clinically implemented.
RESULTS
Study Demographics
Of the 125 drugs evaluated, 67 (53.6%) had 1 published pharmacogenomic study, regardless of the journal's IF. First, we examined the number of pharmacogenomic publications per drug according to drug approval year ( Fig. 1) . We did not detect any trends suggesting that time since FDA approval was correlated with the number of pharmacogenomic publications. Instead, there were relatively few oncology drugs for which a large amount of pharmacogenomic research had been performed. In total, 19 of 67 drugs (28.4%) had >20 published pharmacogenomic studies. Publications describing 1 positive genetic association vastly outweighed the number of publications reporting only negative associations (Supporting Fig. 1 ).
Of the drugs evaluated, 56 (44.8%) were reported to have positive oncologic pharmacogenomic associations in journals with an IF 5 (Supporting Table 2 ). These 56 drugs were supported by an average of 8 publications per drug (range, 1-72 publications per drug), representing 173 unique, high-impact publications that initially were critically appraised. In total, 154 publications were brought forward for further analyses (see Supporting Results). Overall, 246 genes were reported with positive pharmacogenomic findings in the included publications, comprising 436 unique gene-publication pairs. Many genes were studied in multiple publications. Indeed, we observed that 35.1% of these unique gene-publication pairs were comprised of a relatively small list of key pharmacogenes (Fig. 2) . These included the adenosine triphosphate-binding cassette (ABC), cytochrome P450 (CYP), glutathione S-transferase (GST), Fc fragment of immunoglobulin G receptor (FCGR), solute carrier (SLC), ERCC excision repair (ERCC), and vascular endothelial growth factor (VEGF) gene families 22 as well as the methylenetetrahydrofolate reductase (MTHFR) gene.
Supporting Figure 2 displays the 6 most common clinical outcomes analyzed for pharmacogenomic association. Progression-free survival (including disease-free, event-free, recurrence-free, and relapse-free survival) was the most common clinical outcome studied across the critically analyzed studies (in 56 of 154 publications; 36.4%). Overall survival and the response rate were analyzed in 29.2% and 27.3% of studies, respectively (see Supporting Results for additional details).
The sample size distribution of the publications analyzed is displayed in Figure 3 . Sizes ranged from 6 to 4925 patients (median, 179 patients). The highest percentage of studies (29.9%) had sample sizes between 101 and 200 patients; it is noteworthy that only 4.3% of studies in this range resulted in a draft CDS summary (see below). In contrast, only 6.5% of analyzed studies had sample sizes >1000 patients, and 20.0% of these resulted in a draft CDS summary.
Of the publications critically assessed, 11 of 154 (7.1%) ultimately described drug-genetic pairs that resulted in draft CDS summaries. Detailed reasons explaining why the remaining 143 publications were deemed not actionable (and did not result in a summary) are available in the Supporting Results.
Potentially Clinically Actionable Associations
Our critical analysis resulted in 12 drugs that had genetic information we deemed potentially clinically actionable. These highest level pharmacogenomic results are provided in Table 1 .
5-12,23-33 Six unique drugs-asparaginase, cisplatin, doxorubicin, lapatinib, sunitinib, and vincristine-were identified as having novel, potentially clinically actionable pharmacogenomic information through our analysis. An additional 13 drugs that were not currently clinically actionable were deemed to be deserving of future follow-up (see Supporting Table 3 and Supporting Results).
Consideration of germline gene-disease (as distinct from the above gene-drug) associations that also directly The FDA label for lapatinib indicates that HLA-DQA1*02:01 has been associated with hepatotoxicity, but a specific clinical recommendation/action is not provided in the FDA label.
Germline Pharmacogenomics in Oncology/Wellmann et al
Cancer impact oncology prescribing revealed 3 additional drugs with actionable prescribing information included in their FDA labeling: olaparib/ breast cancer (BRCA), rucaparib/ BRCA, and dabrafenib/glucose-6-phosphate dehydrogenase (G6PD) (Supporting Table 4 ).
AGREE II Analysis Results
Draft CDS summaries for the potentially clinical actionable drug-genetic pairs were developed and then subjected to final, formal AGREE appraisal. The AGREE scores for each CDS summary, the overall mean 6 standard deviation (SD) scores for each domain, and the ultimate determination surrounding clinical actionability are displayed in Table 2 . Of the CDS guidelines that were written for the 6 drug-genetic pairs that were denoted a priori as deserving CDS based on FDA/CPIC designations, the mean 6 SD scores were: domain 1 (scope and purpose), 97.6 6 1.9 (range, 95.8-100.0); domain 3 (rigour of development), 93.2 6 9.1 (range, 79.6-98.6); domain 4 (clarity of presentation), 90.9 6 8.0 (range, 81.5-98.6); and domain 5 (applicability), 86.5 6 4.0 (range, 80.6-88.9). In addition, the mean 6 SD overall quality score for these CDS guidelines was 6.5 6 0.6 (range 5.7-7.0). Notably, the summaries for capecitabine/fluorouracil (dihydropyrimidine dehydrogenase [DPYD] ) and mercaptopurine/thioguanine (thiopurine S-methyltransferase [TPMT]) received the maximum possible mean overall quality score of 7. Scores for our 6 novel drugs were similarly high for domain 1 (scope and purpose) and domain 3 (rigour of development), whereas scores for domain 4 (clarity of presentation) and domain 5 (applicability) were lower. The mean 6 SD scores were as follows: domain 1, 90.6 The mean overall quality score for these 6 drugs was 4.6 6 0.4 (range, 4.3-5.8). Of these drugs, the summary for vincristine/reference single-nucleotide polymorphism 924607 (rs924607) scored the highest, with an overall mean 6 SD quality score of 5.8 6 1.3.
We chose a standard of requiring 100% consensus among AGREE scorers on the "recommend/do not recommend" assessment before affirming a summary as ultimately actionable for clinical implementation. The CDS summaries for all but 1 of the draft drug-genetic pairs (sunitinib/rs307826) attained 100% agreement among scorers.
As an illustrative example, Figure 4 21,32,33 displays the CDS summary for vincristine that was recommended Abbreviations: CYP2D6, cytochrome P450 family 2 subfamily D member 6; DYPD, dihydropyrimidine dehydrogenase; HLA-DQA1, human leukocyte antigen DQ a1; rs, reference single-nucleotide polymorphism number; SD, standard deviation; TPMT, thiopurine S-methyltransferase; UGT1A1, uridine diphosphate glucuromosyltransferase family 1 member A1.
for implementation. This CDS guideline is currently delivered to institutional oncologists through our Genomic Prescribing System. 18, 21 Details regarding the evidence supporting this specific summary and the development of its CDS language are available in the Supporting Results. CDS summaries exist in the Genomic Prescribing System for all 12 drugs that were deemed clinically actionable through this study.
DISCUSSION
The clinical use of genomic information in oncology has become commonplace, with the vast amount of actionable information consisting of somatic alterations from tumor sequencing. However, for the comprehensive clinical care of oncology patients in the precision medicine era, somatic information might also be integrated with patient-specific germline information. To our knowledge, ours is the first study to comprehensively and critically appraise the available evidence for using germline information during the prescribing of oncology drugs and to propose actionable CDS summaries based on published evidence. We observed that there is now a critical mass of clinically actionable germline pharmacogenomic associations, of which onehalf have been well known for decades and the other one-half were previously unrecognized but recently identified based on discovery research. In total, we identified 12 drugs for which consistent germline pharmacogenomic information has sufficient evidence to deserve point-of-care clinical consideration. Deployment of CDS tools for these germline variants within ongoing institutional implementation efforts (coupled with appropriate genotyping) will permit future studies of clinical utility for these germline pharmacogenomic biomarkers.
Oncologists are uniquely primed for the idea of assimilating pharmacogenomic information into treatment decision making. A survey of over 10,000 United States physicians indicated that oncologists were >5 times more likely to have ordered a pharmacogenomic test in Figure 4 . This is an example of a clinical decision support summary written for vincristine/rs924607 TT and deployed in the Genomic Prescribing System. This summary received scores of 100.0 for domain 1 (scope and purpose), 97.2 for domain 3 (rigour of development), 76.4 for domain 4 (clarity of presentation), and 68.8 for domain 5 (applicability) on our modified Appraisal of Guidelines for Research and Evaluation (AGREE II) scoring instrument. Furthermore, the overall mean quality score for this summary was 5.8. The unanimous recommendation was in support of clinical deployment of this association. Therefore, it is now being delivered to clinicians (for genotyped patients) using our institutional Genomic Prescribing System (see O'Donnell et al Germline Pharmacogenomics in Oncology/Wellmann et al Cancer July 15, 2018 the past 6 months compared with general or family practitioners. 34 Perhaps this should not be surprising, given that oncologists are well versed in making decisions about oncologic therapies based on tumor genomics. 35, 36 Indeed, oncology practices already have had to solve many of the barriers of genomic clinical implementation. These include finding trusted laboratories to perform the testing, managing cost hurdles and insurance coverage questions, pursuing results in a timely fashion, storing results within the electronic health record, and communicating results with patients. [36] [37] [38] Changes in FDA labeling only comprise a small part of the key step in learning about important genomic information, and most oncologists probably depend on other sources to develop and hone this proficiency (eg, national meetings, American Society of Clinical Oncology guidelines, local/institutional genomic "tumor boards"). [39] [40] [41] Furthermore, oncologists may discover that pharmacogenomics is useful in multiple facets of oncologic care. The utility of certain results, in fact, may change based on the disease setting. For example, if the treatment goal is to cure the patient, then guidelines for gene-drug interactions that predict a greater response to a drug for those carrying a certain genotype may be more desirable than guidelines that warn of a modest toxicity risk. Conversely, in the palliative treatment setting, avoiding toxicity may be considered more important; therefore, guidelines indicating that patients carry an increased risk of side effects may allow providers to successfully avoid a harmful drug altogether or to adopt upfront dose-reduction.
To translate germline genomic findings into clinical practice, the first step is to define and characterize which information is potentially ready for consideration of implementation. Several gene/drug examples have been described for decades, 1 with various degrees of implementation across oncology institutions and practices. [42] [43] [44] We used a previously published method 19 to critically assess the vast number of germline pharmacogenomic studies about oncology drugs. It is noteworthy that the majority of drugs have had positive pharmacogenomic associations described about them (67 of the 125 drugs), with published associations for 12 drugs withstanding rigorous evidence standards required for clinical actionability. Our data, perhaps not surprisingly, also suggest that the more pharmacogenomic publications a drug-genetic pair has, the greater the likelihood that the reported association is truly clinically actionable, illustrating the importance of replication. 45 We observed that very few of the genomic polymorphisms supporting the associations for those 12 drugs are currently reported alongside somatic markers on our institutional Clinical Laboratory Improvement Amendments-accredited laboratory OncoPanel (J. Segal, personal communication), highlighting the need for more comprehensive or additional genotyping to make implementation of such germline markers a reality.
In determining which pharmacogenomic information should be implemented, we posit that several factors should be carefully considered. We were unable to detect clinically actionable associations for 11 of the top 20 drugs with the highest number of pharmacogenomic publications, although many more studies reported positive associations than negative associations for these drugs. It seems obvious that this may be because of publication bias; therefore, it must be kept in mind that the quality of published studies (and the quality of replication), not the total number of studies, should drive actionability determinations. In addition, progression-free survival and overall survival necessarily encapsulate prognostic information about the disease; therefore, published "pharmacogenomic studies" examining these phenotypes in fact may be describing disease-related genetic associations and not pharmacogenomic associations. If more oncologic pharmacogenomic studies in the future were to include control groups and/or would analyze nonprognostic outcomes (like response), then an increased number of truly pharmacogenomic associations could potentially be identified. Increasing the power of future studies through analysis of larger sample sizes will also be essential.
In conjunction with a rigorous assessment of what to implement, it is of great importance to also critically appraise proposed clinical guidelines before implementation. In general, scores from a modified version of a well established, validated tool (the AGREE II instrument) were high for our proposed germline pharmacogenomic CDS summaries. It is important to note that we adopted a stringent requirement of unanimous recommendation for clinical deployment among our 4 independent AGREE scorers for guideline implementation. Although certain CDS summaries scored lower on the domains of clarity of presentation and applicability, several previous studies have placed a particular emphasis on the rigour of development domain, suggesting that this domain is indicative of high-quality guidelines. [46] [47] [48] [49] Notably, all of our guidelines scored well above the common "high-quality" threshold of 60% on this domain. Furthermore, many past studies have classified guidelines as "recommended" for implementation if the overall quality score exceeded 50%. 50, 51 All of our proposed guidelines exceeded this threshold. Finally, both the domain and overall quality Original Article scores of our CDS recommendations were very similar to, and in many cases higher than, AGREE II scores for guidelines currently implemented in clinical practice. [51] [52] [53] [54] Our study had limitations. Because we used the criterion of only evaluating studies published in journals with an IF 5, it is possible that we missed other potentially actionable germline associations, although this would seem unlikely. In addition, our analyses were limited to unique drug-genetic associations in which the genetic association could confidently be attributed to a clinical outcome from a specific oncology drug. Therefore, we did not include genetic signals associated with outcomes from multidrug regimens for which the phenotype of interest may have represented a composite drug outcome ("regimen effect"). Finally, our comprehensive critical appraisal process of the published literature specifically excluded publications for which the studied germline genomic associations represented gene-disease, as opposed to gene-drug, interactions. Nevertheless, given the recent impact of several germline gene-disease relations to directly impact the prescribing of certain oncology drugs, we comprehensively analyzed FDA labels for gene-disease interactions that had actionable prescribing recommendations and included the findings in our results. We acknowledge that some other potentially relevant or emerging germline associations may have been missed. For example, the germline mutation epidermal growth factor receptor threonine-to-methionine substitution at position 790 (EGFR T790M) is a predisposing factor for lung cancer and frequently confers resistance to tyrosine kinase inhibitors when present in the tumor genome. 55, 56 As a nononcologic example, some diseases that are caused by germline mutations may be exacerbated by cancer medications, as is the case with Charcot-Marietooth neuropathy and vincristine. 57, 58 These examples represent additional important considerations during oncologic prescribing.
The direct application of this study's findings will be actualized through clinical implementations that are now ongoing at many institutions, including ours. We have designed a pharmacogenomic CDS system that allows for the availability of pre-emptive germline results at the point of care. 18 The goal of these efforts is to permit eventual realization of a clinical care model that allows consideration of both germline and somatic genomic information at the time of prescribing. Clinicians will then be able to test the hypothesis that doing so ultimately improves clinical decision making, aids in prescribing, reduces toxicities, improves response rates, and benefits patients. This of course represents both the challenge and the promise of precision medicine in the genomic era.
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